Upon a simple numerical comparison, we found that the results obtained within our population for hormone therapy in prostate cancer and for ovarian (olaparib), lung (alectinib, lorlatinib, durvalumab), thyroid (lenvatinib), breast (palbociclib after aromatase inhibitors), head and neck (nivolumab), and melanoma (nivolumab, pembrolizumab, ipilimumab) were largely similar to the published results. Here, CYP19A1 is linked to Familial prostate cancer.